V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency. Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase II/III randomized, controlled trial

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency. The peer-reviewed publication heightens international understanding of APDS, a rare and recently characterized immunodeficiency

Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kδ inhibitor under investigation for APDS, a rare primary immunodeficiency.

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Medical Officer, Anurag Relan, will attend the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California, November 7-10, 2022.

Pharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference in London, November 15-17, 2022.

Pharming Group N.V. announces that its Chief Financial Officer, Jeroen Wakkerman, will present at the Stifel Healthcare Conference in New York, November 15-16, 2022.

Pharming Group N.V. announces today that its Marketing Authorisation Application (MAA) for leniolisib has been validated for scientific evaluation under an accelerated assessment by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

Pharming Group N.V. presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022.

Pharming Group N.V. confirms it will announce financial results for the nine months ended September 30, 2022 on Thursday, October 27, 2022.

Pharming Group N.V. announces that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents 12 years or older.